Analysts Set Establishment Labs Holdings Inc. (NASDAQ:ESTA) Price Target at $100.25

Establishment Labs Holdings Inc. (NASDAQ:ESTA) has been assigned an average recommendation of “Moderate Buy” from the nine analysts that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $100.25.

ESTA has been the subject of several recent research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Establishment Labs in a research report on Wednesday, June 24th. BTIG Research raised their target price on shares of Establishment Labs from $96.00 to $103.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Citigroup upgraded shares of Establishment Labs from a “neutral” rating to a “buy” rating and set a $92.00 target price on the stock in a report on Thursday, August 13th. TD Cowen lifted their target price on shares of Establishment Labs from $95.00 to $117.00 and gave the stock a “buy” rating in a research note on Monday, August 3rd. Finally, Needham & Company LLC increased their price target on shares of Establishment Labs from $86.00 to $95.00 and gave the company a “buy” rating in a research report on Thursday, August 6th.

Establishment Labs Stock Performance

Establishment Labs stock opened at $69.33 on Thursday. The firm has a fifty day simple moving average of $84.67 and a two-hundred day simple moving average of $74.92. The company has a quick ratio of 2.52, a current ratio of 3.84 and a debt-to-equity ratio of 12.11. Establishment Labs has a twelve month low of $36.53 and a twelve month high of $97.59. The company has a market capitalization of $2.07 billion, a PE ratio of -52.92 and a beta of 1.07.

Establishment Labs (NASDAQ:ESTA) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.05). The company had revenue of $67.54 million during the quarter, compared to analysts’ expectations of $65.79 million. Establishment Labs had a negative return on equity of 196.69% and a negative net margin of 15.82%.The firm’s quarterly revenue was up 31.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.57) EPS. Research analysts expect that Establishment Labs will post -1.15 EPS for the current year.

Hedge Funds Weigh In On Establishment Labs

Hedge funds and other institutional investors have recently modified their holdings of the company. HighTower Advisors LLC grew its position in shares of Establishment Labs by 3.2% in the 2nd quarter. HighTower Advisors LLC now owns 9,517 shares of the company’s stock worth $817,000 after buying an additional 293 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Establishment Labs by 1.2% during the second quarter. Geode Capital Management LLC now owns 25,917 shares of the company’s stock valued at $1,105,000 after acquiring an additional 299 shares in the last quarter. Brian Low Financial Group LLC lifted its stake in Establishment Labs by 10.2% in the first quarter. Brian Low Financial Group LLC now owns 4,598 shares of the company’s stock worth $261,000 after acquiring an additional 424 shares during the period. KBC Group NV purchased a new stake in Establishment Labs in the first quarter worth $28,000. Finally, Northwestern Mutual Wealth Management Co. bought a new stake in Establishment Labs in the second quarter valued at $43,000. 72.91% of the stock is owned by institutional investors.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.